Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,714 across all filing types
Latest filing 2023-08-22 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 年半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, cash flow, earnings per share, and asset information. It also includes shareholder information and notes on changes in controlling shareholders, which are typical components of an interim or quarterly financial report. The document length is 2566 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-22 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' opinion on specific matters discussed at the company's 10th board of directors' second meeting. It includes opinions on related party transactions, guarantees, and a special report on the use of raised funds for the half-year period ending June 30, 2023. The document references regulatory guidelines and provides assurance on compliance and accuracy of the special report. It is not a full financial report but rather an audit/opinion related to specific financial and governance matters. The document length is short (788 characters), and it contains detailed independent directors' opinions, which aligns with an Audit Report / Information filing rather than a full Annual or Interim Report. Therefore, the classification is AR (Audit Report / Information). H1 2023
2023-08-22 Chinese
关于募集资金专户完成销户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the completion of the closure of special accounts for raised funds by the company. It details the background of the fundraising, the management and regulatory compliance of the funds, and the final closure of the accounts. There are no financial statements, no detailed financial performance data, or comprehensive report content. The document is relatively short (2371 characters) and serves as a formal notification of a corporate action related to capital management. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2023-08-18 Chinese
关于更换持续督导保荐代表人的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for a company's non-public stock issuance project. It details personnel changes in the sponsor representatives responsible for overseeing the use of raised funds. There is no financial data, report, or detailed analysis presented. The document is a regulatory announcement about management of the sponsorship role related to financing oversight, not a financial report or earnings release. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-07-31 Chinese
关于启迪药业集团股份公司2023年第一次临时股东大会的法律意见书
Regulatory Filings
2023-07-24 Chinese
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2023 first extraordinary general meeting of shareholders of the company. It details the meeting date, attendance, voting results on specific proposals, and legal opinions confirming the validity of the meeting and voting process. There is no financial data or detailed report content, only the official voting results and meeting summary. The document length is short (1795 characters) and it serves as an official announcement of voting results rather than the full meeting materials or reports. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-07-24 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.